1. Volume 16, Issue 15, Pages 1515-1524 (November 2015)
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial 
Prof R Paul Symonds, FRCR, Prof Charlie Gourley, PhD, Susan Davidson, MD, Karen Carty, Elaine McCartney, BSc, Debbie Rai, PhD, Susana Banerjee, PhD, David Jackson, PhD, Rosemary Lord, MBChB, Mary McCormack, FRCR, Emma Hudson, MBBCh, Prof Nicholas Reed, MBBS, Maxine Flubacher, MBBCh, Petra Jankowska, FRCR, Melanie Powell, MD, Prof Caroline Dive, PhD, Prof Catharine M L West, PhD, James Paul, BSc 
The Lancet Oncology 
Volume 16, Issue 15, Pages (November 2015)
DOI: /S (15)00220-X
Copyright © 2015 Symonds et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
*One patient in this group was given chemotherapy but did not receive any trial drug. †Two patients withdrew from the study before starting treatment and are censored for progression-free and overall survival at this point.
The Lancet Oncology  , DOI: ( /S (15)00220-X)
Copyright © 2015 Symonds et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Progression-free survival
The Lancet Oncology  , DOI: ( /S (15)00220-X)
Copyright © 2015 Symonds et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3 Overall survival
The Lancet Oncology  , DOI: ( /S (15)00220-X)
Copyright © 2015 Symonds et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4
European Organisation for Research and Treatment of Cancer QLQ-C30 global health status by timepoint
The circle is an outlier datapoint.
The Lancet Oncology  , DOI: ( /S (15)00220-X)
Copyright © 2015 Symonds et al. Open Access article distributed under the terms of CC BY Terms and Conditions

6. Figure 5 Mean sVEGFR2 concentration (log 10) by timepoint
Error bars are standard errors. sVEGFR2=plasma-soluble VEGFR2. *Two baseline measurements were taken for each patient (these are replicate results).
The Lancet Oncology  , DOI: ( /S (15)00220-X)
Copyright © 2015 Symonds et al. Open Access article distributed under the terms of CC BY Terms and Conditions